Welcome to our dedicated page for Nuvectis Pharma news (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma stock.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is a clinical-stage biopharmaceutical company developing precision oncology small molecule therapies, and its news flow reflects the progress of these programs. Company announcements frequently highlight clinical milestones for its lead SRC/YES1 kinase inhibitor NXP900 and its GCN2 activator NXP800, as well as corporate and financial updates.
News items for Nuvectis often cover clinical trial developments, including the completion of the NXP900 Phase 1a dose escalation study in advanced solid tumors, results from a drug-drug interaction study in healthy volunteers, and the initiation of the Phase 1b program. Updates describe the single-agent Phase 1b component in genomically selected advanced cancers and combination studies with EGFR and ALK inhibitors in non-small cell lung cancer, including a study combining NXP900 with osimertinib in EGFR-mutated NSCLC that has developed resistance.
Investors and followers of NVCT can also find scientific conference coverage in the company’s news, such as poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. These items summarize emerging safety, pharmacokinetic, pharmacodynamic and preclinical data that inform the biomarker-based strategy for NXP900.
Additional news includes pipeline updates for NXP800, including final Phase 1b data in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer and the company’s decision to explore potential opportunities for NXP800 in other cancer types. Nuvectis also issues financial results and business highlights via quarterly earnings press releases, along with corporate developments such as board appointments and participation in investment conferences. For investors tracking NVCT, this news stream provides ongoing insight into clinical progress, scientific rationale and corporate strategy.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported significant advancements in 2022, highlighted by FDA's Fast Track Designation for NXP800 aimed at treating ARID1A-mutated ovarian carcinoma. The ENOT and GOG Foundation will spearhead the Phase 1b clinical trial for NXP800. Additionally, the IND submission and Phase 1 study for NXP900 are anticipated in the first half of 2023. Financially, the company ended 2022 with $20 million in cash and an increased net loss of $19.1 million, reflecting rising R&D costs at $13.2 million. Nuvectis remains optimistic about its programs, emphasizing the year as potentially transformational for its drug candidates.
Nuvectis Pharma (NASDAQ: NVCT) announced promising results for its drug candidate NXP800 at the ESMO Gynecological Cancers Congress. In two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, NXP800 demonstrated significant tumor growth inhibition (TGI) of 70% and 82%, outperforming cisplatin's TGI of 42% and 20%, respectively.
Dr. Susana Banerjee highlighted the urgent need for new therapies for ovarian cancer patients, particularly those with ARID1a mutations, which are linked to poor outcomes. NXP800 is set to enter a Phase 1b clinical trial, following its Fast Track Designation from the FDA for treating platinum-resistant ovarian carcinoma.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced a publication in the Journal of Experimental Medicine regarding NXP900's efficacy in treating metastatic castration resistant prostate cancer (mCRPC) resistant to enzalutamide (XTANDI®). The publication suggests that NXP900, also known as eCF506, may reverse resistance to XTANDI® when combined with it. The CEO, Ron Bentsur, emphasized the drug's potential as a leading SRC/YES1 kinase inhibitor, with expectations for clinical advancement. Nuvectis Pharma is focused on addressing unmet medical needs in oncology and is also developing NXP800, which targets ARID1a mutations.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced a collaboration with ENGOT and GOG Foundation to conduct the NXP800 Phase 1b clinical trial targeting ARID1A-mutated ovarian clear cell and endometrioid carcinomas. Dr. Susana Banerjee leads the trial, with co-leads Dr. Shannon Westin and Dr. Ramez Eskander. The ongoing Phase 1a trial demonstrates promising results, supporting the safety and effectiveness of NXP800. The FDA has granted Fast Track Designation for the drug, highlighting its potential in addressing significant unmet medical needs in oncology.
Nuvectis Pharma (NASDAQ: NVCT) announced on December 1, 2022, that the FDA granted Fast Track Designation to its drug candidate NXP800, aimed at treating platinum-resistant, ARID1A-mutated ovarian carcinoma. This designation highlights the drug's potential to meet urgent medical needs in oncology. CEO Ron Bentsur expressed confidence in NXP800's ability to improve patient outcomes. Nuvectis is also developing NXP900, a SRC/YES1 kinase inhibitor, currently in preclinical studies. Fast Track allows for expedited drug development and review for serious conditions.
Nuvectis Pharma (NASDAQ: NVCT) announced its Q3 2022 financial results and progress in drug development. The Phase 1a trial for NXP800 is ongoing, with Phase 1b set to start in Q1 2023. Positive preclinical data for NXP800 was reported, highlighting its potential for treating ARID1a-mutated gastric cancer. NXP900 is advancing towards IND submission expected in Q1 2023, with new insights on its activity profile. Cash reserves grew to $23.6 million, but net losses increased to $5.9 million from $4.7 million year-on-year, primarily due to R&D costs.
Nuvectis Pharma, based in Fort Lee, NJ, announced upcoming presentations at the 34th EORTC-NCI-AACR Symposium from October 26-28, 2022. The two posters will address key developments in their drug candidates, NXP800 and NXP900. NXP800 focuses on HSF1 pathway inhibition, with a predictive biomarker identified for therapeutic responsiveness. NXP900 shows a significantly higher sensitivity in cancer cell lines compared to dasatinib, suggesting potential advantages for certain patient subgroups. Nuvectis remains committed to addressing unmet medical needs in oncology.
Nuvectis Pharma, a biopharmaceutical firm focused on innovative oncology treatments, announced management participation at the Roth Inaugural Healthcare Opportunities Conference.
The event is scheduled for October 6, 2022, at 8:15 a.m. ET in New York.
Nuvectis is advancing its pipeline, which includes NXP800 and NXP900, aimed at treating unmet medical needs.
Nuvectis Pharma announced the formation of a Scientific Advisory Board (SAB) on September 28, 2022, to enhance its research and development strategy. The SAB comprises prominent experts in oncology, including Prof. Shannon N. Westin, Prof. Gordon B. Mills, and Prof. Paul Workman. Chairman and CEO Ron Bentsur emphasized the importance of this collaboration in advancing the company's innovative precision medicine initiatives, particularly for treating serious unmet medical needs in oncology.
Nuvectis Pharma announced promising preclinical results for NXP800, targeting ARID1a-mutated gastric carcinoma. Following successful outcomes in ovarian carcinoma models, the company is optimistic about expanding NXP800's development to gastric cancer, which affects 20-25% of the 26,000 annual U.S. diagnoses. The current prognosis for gastric cancer is poor, with a 5-year survival rate of just 32%. Nuvectis is on track with the Phase 1a study and anticipates beginning Phase 1b in Q1 2023.
FAQ
What is the current stock price of Nuvectis Pharma (NVCT)?
What is the market cap of Nuvectis Pharma (NVCT)?
